QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna™ TME panel ...
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) has announced the U.S. Food and Drug Administration (FDA) approval of its therascreen ® KRAS RGQ ...
First and only company with 100 approved and active companion diagnostic indications for next-generation sequencing in the United States and Japan, setting the standard for high-quality genomic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback